Fiera Capital (Europe)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fiera Capital (Europe)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-515,289	Closed	-$6.93K	–	50
2014 Q4	$6.93K	Buy	515,289 +514,625	+77,504%	+$42.8M	5.09%	5
2014 Q3	$48K	Hold	664	–	–	0.03%	52
2014 Q2	$41K	Buy	+664	New	+$40.1K	0.03%	52
2014 Q1	–	Sell	-446	Closed	-$31K	–	54
2013 Q4	$31K	Buy	+446	New	+$30.3K	0.02%	49

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fiera Capital (Europe)'s BMRN Position: Q1 2015 in Review

Fiera Capital (Europe) sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2015, closing a stake of 515,289 shares — an estimated $6.93K sold.

Fiera Capital (Europe) first reported a position in BMRN in Q4 2013 and held it in 4 quarters. The position peaked at $48K in Q3 2014. 377 funds tracked by Wall St. Rank hold BMRN as of Q1 2015.

Fiera Capital (Europe) reported no remaining BioMarin Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Fiera Capital (Europe) sold 515,289 BioMarin Pharmaceuticals shares in Q1 2015, an estimated $6.93K.
Fiera Capital (Europe) first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 4 quarters.
Fiera Capital (Europe)'s BioMarin Pharmaceuticals position peaked at $48K in Q3 2014.
377 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2015.

Based on Fiera Capital (Europe)'s 13F filing for Q1 2015, filed 12 May 2015.